In Law360 and Managed Healthcare Executive article, health care partner Margaux Hall, who leads the firm’s drug pricing and price reporting group, discussed the Centers for Medicare & Medicaid Services release of the list including the first 10 drugs to be negotiated under the Inflation Reduction Act. The legislation allows CMS to negotiate certain Medicare drug prices.
Margaux expects further scrutiny of CMS’s authority to negotiate drug prices, as well as potential litigation and market ramifications. “It is possible that litigants in existing lawsuits may respond to the publication of the drug listing and seek further legal redress. Across the broader pharmaceutical industry, I expect to see lots of dissection of this list to try to reverse engineer the agency’s criteria and processes for selection. I also expect follow-on analysis about implications for drugs that may be selected in later years,” said Margaux.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find our more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.